TY - JOUR
T1 - Toxicity of Intrathecally Administered Cytotoxic Drugs and Their Antitumor Activity against an Intrathecal Walker 256 Carcinosarcoma Model for Meningeal Carcinomatosis in the Rat
AU - Kooistra, Kimberly L.
AU - Rodriguez, Moses
AU - Powis, Garth
PY - 1989/2/15
Y1 - 1989/2/15
N2 - Meningeal carcinomatosis in humans is refractory to most attempts at therapy and has a grave prognosis. As part of a search for new agents to treat meningeal carcinomatosis, the toxicity of a series of antitumor agents administered through an implanted catheter directly into the cerebrospinal fluid (CSF) of the lumbar spinal cord of 200-g rats has been examined. The highest non-toxic dose (HNTD) of the agents producing no signs of histological damage, motor dysfunction, or neuro-behavioral changes was bleomycin (80 µg), cytarabine (640 µg), dacar-bazine (1 µg), doxorubicin (20 µg), 5-fluorouracil (150 µg), methotrexate (1000 µg), mitomycin C (10 µg), and triethylene phosphoramide (800 µg). No toxicity was observed at the highest dose that could be administered because of limited solubility of 1,3-6/y(2-chloroethyl)-l-nitrosourea (100 µg), or diaziquone (70 µg). The rat model gave reasonable prediction of the toxicity of antitumor agents that have been administered intra-CSF to humans but with a tendency to underpredict toxicity. The antitumor activity of the agents administered intra-CSF at the HNTD against a Walker 256 carcinosarcoma model for meningeal carcinomatosis in the rat was examined. Diaziquone, doxorubicin, methotrexate, and mitomycin C gave a 25% or greater increase in lifespan and diaziquone and mitomycin C gave some long-term survivors. BCNU, bleomycin and 5-fluo-rouracil gave less than a 25% increase in lifespan. When mitomycin C was administered intra-CSF at the HNTD and diaziquone at the limit of solubility daily for 4 days there was no toxicity and an increase in survival of Walker 256 carcinosarcoma tumored animals compared to animals administered a single daily dose. Intrathecal diaziquone was more active against meningeal Walker 256 carcinosarcoma than i.v. diaziquone. Intravenous methotrexate had no activity against meningeal Walker 256 carcinosarcoma. We conclude that intra-CSF administration of some anticancer agents such as diaziquone and mitomycin C at doses that do not produce toxicity can significantly increase the survival of rats with experimental meningeal carcinomatosis.
AB - Meningeal carcinomatosis in humans is refractory to most attempts at therapy and has a grave prognosis. As part of a search for new agents to treat meningeal carcinomatosis, the toxicity of a series of antitumor agents administered through an implanted catheter directly into the cerebrospinal fluid (CSF) of the lumbar spinal cord of 200-g rats has been examined. The highest non-toxic dose (HNTD) of the agents producing no signs of histological damage, motor dysfunction, or neuro-behavioral changes was bleomycin (80 µg), cytarabine (640 µg), dacar-bazine (1 µg), doxorubicin (20 µg), 5-fluorouracil (150 µg), methotrexate (1000 µg), mitomycin C (10 µg), and triethylene phosphoramide (800 µg). No toxicity was observed at the highest dose that could be administered because of limited solubility of 1,3-6/y(2-chloroethyl)-l-nitrosourea (100 µg), or diaziquone (70 µg). The rat model gave reasonable prediction of the toxicity of antitumor agents that have been administered intra-CSF to humans but with a tendency to underpredict toxicity. The antitumor activity of the agents administered intra-CSF at the HNTD against a Walker 256 carcinosarcoma model for meningeal carcinomatosis in the rat was examined. Diaziquone, doxorubicin, methotrexate, and mitomycin C gave a 25% or greater increase in lifespan and diaziquone and mitomycin C gave some long-term survivors. BCNU, bleomycin and 5-fluo-rouracil gave less than a 25% increase in lifespan. When mitomycin C was administered intra-CSF at the HNTD and diaziquone at the limit of solubility daily for 4 days there was no toxicity and an increase in survival of Walker 256 carcinosarcoma tumored animals compared to animals administered a single daily dose. Intrathecal diaziquone was more active against meningeal Walker 256 carcinosarcoma than i.v. diaziquone. Intravenous methotrexate had no activity against meningeal Walker 256 carcinosarcoma. We conclude that intra-CSF administration of some anticancer agents such as diaziquone and mitomycin C at doses that do not produce toxicity can significantly increase the survival of rats with experimental meningeal carcinomatosis.
UR - http://www.scopus.com/inward/record.url?scp=0024505088&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024505088&partnerID=8YFLogxK
M3 - Article
C2 - 2912564
AN - SCOPUS:0024505088
SN - 0008-5472
VL - 49
SP - 977
EP - 982
JO - Cancer Research
JF - Cancer Research
IS - 4
ER -